H2 Haplotype and CYP3As Polymorphisms and the Antiplatelet Response to Clopidogrel

• Status: Completed
• Trial end date: 2006-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study was to assess whether interpatient variability in the platelet response to clopidogrel is partly due to polymorphisms of the hepatic cytochrome P450 (CYP450)3A and of the clopidogrel-P2Y12 receptor genes.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hopital du Sacre-Coeur de Montreal
• Treatments: Clopidogrel; Ticlopidine

Criteria

Inclusion Criteria:

• Documented coronary artery disease (CAD) requiring an elective diagnostic coronary angiography with or without percutaneous coronary intervention (PCI)

Exclusion Criteria:

• Major bleeding disorders or active bleeding;

• Acute MI within 14 days of recruitment;

• Unstable angina with ST-segment changes of > or = 1 mm in at least two contiguous electrocardiographic leads at rest, a troponin level of > 0.06 ug/L or both within 14 days of recruitment;

• Stroke within the last 3 months;

• Platelet count < 100 x 109/L;

• Prothrombin time > 1.5 times control;

• Hematocrit < 25% or hemoglobin level < 100 g/L;

• Alcohol or drug abuse;

• Enrolment in other investigational drug trials within the previous month;

• Use of thienopyridines, glycoprotein (GP) IIb/IIIa inhibitors, warfarin or acenocoumarol within the prior week;

• Allergic reaction or any contraindication to clopidogrel or aspirin.